Evidence-based approach to the introduction of positron emission tomography in ontario, Canada.
暂无分享,去创建一个
A. Laupacis | M. Levine | K. Gulenchyn | L. Levin | W. Evans
[1] W. Oyen,et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with FDG-PET: A randomized study , 2008 .
[2] Y. Ung,et al. A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) , 2008 .
[3] K. Pritchard,et al. A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer , 2008 .
[4] Barry A Siegel,et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Y. Ung,et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. , 2007, Journal of the National Cancer Institute.
[6] R. Coleman,et al. The National Oncologic PET Registry: expanded medicare coverage for PET under coverage with evidence development. , 2007, AJR. American journal of roentgenology.
[7] Peter B Bach,et al. Federal initiatives to support rapid learning about new technologies. , 2007, Health affairs.
[8] Y. Ung,et al. 169 The impact of positron emission tomography (PET) in stage III non-small cell lung cancer: A prospective randomized clinical trial-improving clinical trials accrual using screening log evaluations , 2006 .
[9] S. Tunis,et al. Coverage options for promising technologies: Medicare's 'coverage with evidence development'. , 2006, Health affairs.
[10] J. Rajendran,et al. Expanding role of positron emission tomography in cancer of the uterine cervix. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] H. Groen,et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Laupacis,et al. Diagnostic imaging in Canada. , 2005, HealthcarePapers.
[13] Hain Sf,et al. Positron emission tomography in uro-oncology , 2005 .
[14] M. King,et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Steven Piantadosi,et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. , 2003, The New England journal of medicine.
[16] M. Boers,et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.
[17] J. Mortensen,et al. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. , 2001, The Lancet. Oncology.
[18] L. Hooft,et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. , 2001, The Journal of clinical endocrinology and metabolism.
[19] D K Owens,et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.
[20] S S Gambhir,et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] R. Hustinx,et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose , 1996, European Journal of Nuclear Medicine.
[22] J S Fowler,et al. A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] Wang Jun. Effectiveness of Positron Emission Tomography in the Preoperative Assessment of Patients with Suspected Non-small-cell Lung Cancer:The PLUS Multicentre Randomized Trial , 2005 .